Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Livio Pagano, Marco Vignetti, Paola Fazi, Giuseppe Cimino, Giovanni Martinelli, D Di Raimondo, Felicetto Ferrara, Giovanna Meloni, Achille Ambrosetti, Giovanni Quarta, Giovanna Rege Cambrin, Loredana Elia, Raffaello Bertieri, Luciana Annino, Robin Foa', Michele Baccarani, Franco Mandelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

247 Citazioni (Scopus)

Abstract

Thirty elderly (> 60 years) Philadelphia chromosome–positive (Ph ) patients with acute lymphoblastic leukemia (ALL) received imatinib, 800 mg daily, associated to steroids without further chemotherapy as frontline treatment. Median age was 69 years (range, 61-83 years). Twenty-nine patients were evaluable for response and all of them obtained a hematologic complete remission, with a median BCR-ABL reduction of 2.9 and 2.0 logs in p190 and p210 cases, respectively. Most of the induction treatment did not require admission of the patients. No major toxicities occurred and the treatment was well tolerated. Median survival from diagnosis was 20 months. This study shows that elderly Ph patients with ALL—often considered eligible only for palliative treatment strategies— may benefit from an imatinibsteroids protocol, which does not require chemotherapy nor a long hospitalization, is feasible, highly active, and associated with a good quality of life
Lingua originaleEnglish
pagine (da-a)3676-3678
Numero di pagine3
RivistaBlood
Stato di pubblicazionePubblicato - 2007

Keywords

  • Philadelphia chromosome positive
  • acute lymphoblastic leukemia
  • elderly
  • imatinib

Fingerprint Entra nei temi di ricerca di 'Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.'. Insieme formano una fingerprint unica.

Cita questo